IRLAB Therapeutics AB (publ) (IRLAB-A.ST)

Compare

7.12

-0.64

(-8.25%)

At close: April 4 at 5:29:44 PM GMT+2

IRLAB to Present Clinical and Preclinical Data at the AD/PD(TM) 2025: 19th International Conference on Alzheimer’s & Parkinson’s Diseases

GOTHENBURG, SE / ACCESS Newswire / April 1, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, April 1, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ...

ACCESS Newswire 3 days ago

6IRA.F
IRLAB Provides Additional Efficacy Data from the Phase IIb Study of Pirepemat in Patients with Parkinson's Disease

GOTHENBURG, SE / ACCESS Newswire / March 28, 2025 /IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, March 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson's ...

ACCESS Newswire 7 days ago

6IRA.F
IRLAB to Initiate a Study of IRL757 in Parkinsons’s Disease with Full Financial Backing from its Development Partner MSRD

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY. GOTHENBURG, SE / ACCESS Newswire / March 27, 2025 /IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments ...

ACCESS Newswire 8 days ago

6IRA.F
IRLAB Publishes Preclinical Data on mesdopetam in the Esteemed European Journal of Neuroscience

GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, ...

ACCESS Newswire 23 days ago

6IRA.F
IRLAB Participates in Stora Aktiedagarna

GOTHENBURG, SE / ACCESS Newswire / March 11, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)(Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will give a presentation ...

ACCESS Newswire 24 days ago

6IRA.F
IRLAB Reports Topline Results from a Phase IIb Study of Pirepemat in Patients with Parkinson's Disease

GOTHENBURG, SE / ACCESS Newswire / March 5, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)(Nasdaq Stockholm:IRLAB A), a company that discovers and develops new treatments for Parkinson's disease, today announces topline results from the Phase IIb ...

ACCESS Newswire 30 days ago

6IRA.F
IRLAB Publishes Phase IIb Data on Mesdopetam in Movement Disorders Clinical Practice

GOTHENBURG, SWEDEN / ACCESS Newswire / February 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for ...

ACCESS Newswire last month

6IRA.F
IRLAB Receives Positive Feedback from EMA Confirming Alignment with FDA on Phase III Program for Mesdopetam

GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 February, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB a company discovering and developing novel treatments for ...

ACCESS Newswire last month

6IRA.F
IRLAB Strengthens Its Value Creation Capabilities Through Extended And Expanded Debt Financing

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)/ IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the duration of the existing loan from Fenja Capital ...

ACCESS Newswire last month

6IRA.F
IRLAB Publishes Full-Year Report for 2024

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 12, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company's ...

ACCESS Newswire last month

6IRA.F
IRLAB: Invitation to the Year-End Report 2024 Presentation and Webcast

GOTHENBURG, SE / ACCESS Newswire / February 7, 2025 /IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 7, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ...

ACCESS Newswire last month

6IRA.F
IRLAB Reports Positive Topline Results from Phase I Study with IRL757 in Healthy Older Adults

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY. GOTHENBURG, SWEDEN / ACCESS Newswire / January 31, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), ...

ACCESS Newswire 2 months ago

6IRA.F
IRLAB to Present at Redeye Investor Forum

GOTHENBURG, SE / ACCESSWIRE / January 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, January 27 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson's disease, ...

ACCESS Newswire 2 months ago

6IRA.F
IRLAB has Received a Waiver from the EMA Regarding Pediatric Studies with Mesdopetam in Parkinson's Disease

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, January 23, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that a waiver regarding ...

ACCESS Newswire 2 months ago

6IRA.F
The Last patient has now Completed the Full Treatment Period in IRLAB's Phase IIb Study with Pirepemat

GOTHENBURG, SE / ACCESSWIRE / January 14, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, January 14, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company that discovers and develops new treatments for Parkinson's ...

ACCESS Newswire 2 months ago

6IRA.F
IRLAB to Present at ABGSC Investor Days on December 4, 2024

GOTHENBURG, SE / ACCESSWIRE / November 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November 29, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ...

ACCESS Newswire 4 months ago

6IRA.F
IRLAB to Present at Redeye Technology & Life Science Day on December 3, 2024

GOTHENBURG, SE / ACCESSWIRE / November 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November 27, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ...

ACCESS Newswire 4 months ago

6IRA.F
Nomination Committee Appointed for IRLAB's Annual General Meeting 2025

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces that the nomination committee ahead of the annual general meeting (AGM) 2025 has been appointed. According to ...

ACCESS Newswire 4 months ago

6IRA.F
IRLAB to Present at BioStock Life Science Summit 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / November 13, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November 13, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson's ...

ACCESS Newswire 4 months ago

6IRA.F
IRLAB Publishes Interim Report for the Period January - September 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / October 30, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the ...

ACCESS Newswire 5 months ago

6IRA.F

Performance Overview

Return	IRLAB-A.ST	OMX Stockholm 30 Index (^OMX)
YTD	-33.77%	-7.89%
1-Year	-52.37%	-9.30%
3-Year	-82.07%	+7.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

IRLAB Therapeutics AB (publ) (IRLAB-A.ST)

IRLAB to Present Clinical and Preclinical Data at the AD/PD(TM) 2025: 19th International Conference on Alzheimer’s & Parkinson’s Diseases

IRLAB Provides Additional Efficacy Data from the Phase IIb Study of Pirepemat in Patients with Parkinson's Disease

IRLAB to Initiate a Study of IRL757 in Parkinsons’s Disease with Full Financial Backing from its Development Partner MSRD

IRLAB Publishes Preclinical Data on mesdopetam in the Esteemed European Journal of Neuroscience

IRLAB Participates in Stora Aktiedagarna

IRLAB Reports Topline Results from a Phase IIb Study of Pirepemat in Patients with Parkinson's Disease

IRLAB Publishes Phase IIb Data on Mesdopetam in Movement Disorders Clinical Practice

IRLAB Receives Positive Feedback from EMA Confirming Alignment with FDA on Phase III Program for Mesdopetam

IRLAB Strengthens Its Value Creation Capabilities Through Extended And Expanded Debt Financing

IRLAB Publishes Full-Year Report for 2024

IRLAB: Invitation to the Year-End Report 2024 Presentation and Webcast

IRLAB Reports Positive Topline Results from Phase I Study with IRL757 in Healthy Older Adults

IRLAB to Present at Redeye Investor Forum

IRLAB has Received a Waiver from the EMA Regarding Pediatric Studies with Mesdopetam in Parkinson's Disease

The Last patient has now Completed the Full Treatment Period in IRLAB's Phase IIb Study with Pirepemat

IRLAB to Present at ABGSC Investor Days on December 4, 2024

IRLAB to Present at Redeye Technology & Life Science Day on December 3, 2024

Nomination Committee Appointed for IRLAB's Annual General Meeting 2025

IRLAB to Present at BioStock Life Science Summit 2024

IRLAB Publishes Interim Report for the Period January - September 2024

Performance Overview